• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?在非小细胞肺癌中靶向MET和EGFR——我们能从最近报道的奥那珠单抗联合厄洛替尼治疗晚期非小细胞肺癌的III期试验中学到什么？
Transl Lung Cancer Res. 2014 Dec;3(6):395-6. doi: 10.3978/j.issn.2218-6751.2014.09.03.
2
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.厄洛替尼联合奥沙利铂抑制表皮生长因子受体突变和肝细胞生长因子过表达的非小细胞肺癌的生长。
Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18.
3
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.随机 II 期试验：奥沙利umab 联合厄洛替尼治疗晚期非小细胞肺癌患者。
J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.
4
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.METLung：奥沙利umab 联合厄洛替尼对比厄洛替尼治疗既往治疗的 IIIB 或 IV 期非小细胞肺癌的 III 期随机试验结果
J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.
5
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变（EGFR）检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂（TKI）药物疗效的预测：一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
6
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.抗MET抗体奥那珠单抗在实体瘤和MET阳性肺癌患者中的I期研究。
Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.
7
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.一线使用奥那珠单抗联合厄洛替尼治疗MET阳性且EGFR突变阳性的非小细胞肺癌患者。
Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.
8
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.一项评估厄洛替尼±奥那珠单抗治疗晚期非小细胞肺癌的安慰剂对照II期研究的生物标志物分析：MET表达水平可预测患者获益情况。
Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31.
9
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.MetLung 试验的治疗原理研究设计：一项 Onartuzumab（MetMAb）联合厄洛替尼与厄洛替尼单药治疗标准化疗后 IIIB 或 IV 期 MET 阳性非小细胞肺癌患者的随机、双盲 III 期研究。
Clin Lung Cancer. 2012 Nov;13(6):500-4. doi: 10.1016/j.cllc.2012.05.009.
10
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.单价抗c-MET抗体奥那珠单抗（MetMAb）在二线和三线非小细胞肺癌中的暴露-反应及肿瘤生长抑制分析
AAPS J. 2017 Mar;19(2):527-533. doi: 10.1208/s12248-016-0029-5. Epub 2016 Dec 27.

引用本文的文献

1
The User's Guide to Amivantamab.阿伐替尼单抗用户指南。
Target Oncol. 2025 Mar;20(2):235-245. doi: 10.1007/s11523-025-01128-6. Epub 2025 Feb 4.
2
Bioinformatics analysis and validation of CSRNP1 as a key prognostic gene in non-small cell lung cancer.CSRNP1作为非小细胞肺癌关键预后基因的生物信息学分析与验证
Heliyon. 2024 Mar 19;10(7):e28412. doi: 10.1016/j.heliyon.2024.e28412. eCollection 2024 Apr 15.
3
The development of amivantamab for the treatment of non-small cell lung cancer.阿美替尼治疗非小细胞肺癌的研究进展。
Respir Res. 2023 Oct 25;24(1):256. doi: 10.1186/s12931-023-02558-4.
4
Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers.靶向细胞外囊泡递送化疗药物治疗三阴性乳腺癌。
Pharmaceutics. 2022 Jan 7;14(1):146. doi: 10.3390/pharmaceutics14010146.
5
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.用于治疗三阴性乳腺癌的靶向脂质体化疗药物
Cancers (Basel). 2021 Jul 26;13(15):3749. doi: 10.3390/cancers13153749.
6
Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.用于三阴性乳腺癌治疗的抗表皮生长因子受体抗体药物偶联物
Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan.
7
A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.一种新型非激动型 c-Met 抗体药物偶联物，在 c-Met 扩增和非扩增癌症中比 c-Met 酪氨酸激酶抑制剂具有更高的效力。
Cancer Biol Ther. 2020 Jun 2;21(6):549-559. doi: 10.1080/15384047.2020.1737490. Epub 2020 Mar 19.
8
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.乳头状肾细胞癌与MET抑制剂综述
Kidney Cancer. 2019 Nov 1;3(3):151-161. doi: 10.3233/KCA-190058.
9
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?MET过表达的非小细胞肺癌中MET和EGFR导向联合治疗：是时候转向更好的生物标志物了吗？
Transl Lung Cancer Res. 2017 Jun;6(3):393-395. doi: 10.21037/tlcr.2017.04.06.
10
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.肝细胞生长因子抑制剂rilotumumab（AMG 102）与厄洛替尼联合用于晚期非小细胞肺癌患者的1/2期研究。
Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

本文引用的文献

1
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.METLung：奥沙利umab 联合厄洛替尼对比厄洛替尼治疗既往治疗的 IIIB 或 IV 期非小细胞肺癌的 III 期随机试验结果
J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.
2
Targeting MET Amplification as a New Oncogenic Driver.针对 MET 扩增作为一种新的致癌驱动因素。
Cancers (Basel). 2014 Jul 22;6(3):1540-52. doi: 10.3390/cancers6031540.
3
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.随机 II 期试验：奥沙利umab 联合厄洛替尼治疗晚期非小细胞肺癌患者。
J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.
4
Erlotinib in previously treated non-small-cell lung cancer.厄洛替尼用于既往接受过治疗的非小细胞肺癌。
N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.

Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

作者信息

Charakidis Michail, Boyer Michael

机构信息

Chris O'Brien Lifehouse, Department of Medical Oncology, Camperdown, NSW 2050, Australia.

出版信息

Transl Lung Cancer Res. 2014 Dec;3(6):395-6. doi: 10.3978/j.issn.2218-6751.2014.09.03.

DOI:10.3978/j.issn.2218-6751.2014.09.03
PMID:25806331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4367679/
Abstract
摘要